# Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -

> **NCT00848445** · PHASE4 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 270 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DEVICE:** Guidant Pulsar Max II or Insignia Plus DR
- **DEVICE:** Atrial pacing preference turned on or off

## Key facts

- **NCT ID:** NCT00848445
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848445, "Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00848445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*